Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has progressed during or w/in 6 mth w/ rituximab or rituximab-containing regimen.
Monotherapy for chronic lymphocytic leukaemia 100 mg/m2 IV infusion over 30-60 min on days 1 & 2 every 4 wk. Monotherapy for indolent non-Hodgkin's lymphomas refractory to rituximab 120 mg/m2 IV infusion over 30-60 min on days 1 & 2 every 3 wk.
Hypersensitivity. Jaundice. Severe bone marrow suppression & severe blood count alterations (leukocyte &/or platelet values dropped to <3,000/microliter or <75,000/microliter, respectively). Infections especially leukocytopenia. Yellow fever vaccination. Major surgery <30 days prior to treatment. Severe hepatic impairment (serum bilirubin >3 mg/dL). Lactation.
Myelosuppression, do not use during severe bone marrow suppression & severe blood count alterations. Infections, discontinue if there are signs of (opportunistic) infections. Skin reactions, discontinue use if severe skin reactions occur. Patients w/ cardiac disorders, monitor closely for patients w/ concurrent or history of cardiac disease. Nausea, vomiting, give antiemetic. Tumor lysis syndrome, preventive measures include adequate vol status, close monitoring of blood chemistry. Anaphylaxis. Extravasation, stop immediately, needle should be removed after short aspiration, affected area of tissue should be cold, arm should be elevated. Non-melanoma skin cancer, periodic skin exam. Hepatitis B reactivation, test for HBV infection before initiating treatment. May affect ability to drive & use machines. Moderate hepatic & severe renal impairment. Contraception, women should not become pregnant during treatment. Male patients should not father a child during & up to 6 mth after treatment. Not to be used during pregnancy & lactation. Ped patients.
Sign Out
